| 4.1 Change in Angioedema Quality of Life (AE‐QoL) Questionnaire scores |
7 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 4.1.1 Avoralstat |
2 |
117 |
Mean Difference (IV, Random, 95% CI) |
‐6.78 [‐11.61, ‐1.95] |
| 4.1.2 Berotralstat |
3 |
130 |
Mean Difference (IV, Random, 95% CI) |
‐15.28 [‐29.42, ‐1.14] |
| 4.1.3 pdC1‐INH |
1 |
113 |
Mean Difference (IV, Random, 95% CI) |
‐10.37 [‐23.47, 2.74] |
| 4.1.4 Lanadelumab |
1 |
117 |
Mean Difference (IV, Random, 95% CI) |
‐14.91 [‐21.89, ‐7.92] |
| 4.2 Difference in EQ‐5D scale compared with placebo |
1 |
133 |
Mean Difference (IV, Random, 95% CI) |
8.90 [2.87, 14.93] |
| 4.3 Change in SF‐36 compared with placebo |
1 |
32 |
Mean Difference (IV, Random, 95% CI) |
9.04 [2.32, 15.76] |
| 4.4 Change in quality of life (all scales) by drug |
9 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 4.4.1 Avoralstat |
2 |
117 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.48 [‐0.84, ‐0.11] |
| 4.4.2 Berotralstat |
3 |
130 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.86 [‐1.67, ‐0.05] |
| 4.4.3 C1‐INH (all forms) |
3 |
162 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.39 [‐0.75, ‐0.04] |
| 4.4.4 Lanadelumab |
1 |
68 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.91 [‐1.43, ‐0.40] |
| 4.5 Change in AE‐QoL total score – head‐to‐head trials |
2 |
|
Std. Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 4.5.1 C1‐INH(SC) + rh hyaluronidase |
1 |
67 |
Std. Mean Difference (IV, Random, 95% CI) |
0.19 [‐0.29, 0.67] |
| 4.5.2 C1‐INH(SC) |
1 |
92 |
Std. Mean Difference (IV, Random, 95% CI) |
0.21 [‐0.20, 0.62] |
